Apply to trial NCT05804227

A few quick questions so the study team can decide if you might be a fit.

RecruitingEarly Phase 1Drug trial

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors

How this works

  1. Answer a few questions

    About 5 to 10 minutes. Skip-friendly where possible.

  2. We forward your profile to the study team

    They see only the answers needed to decide if you can be screened.

  3. The team reaches out to schedule screening

    Usually within a few business days, via the contact you give.

We save your progress under this email so you can come back later, and the study team uses it to reach you.

By clicking Start, you agree to our terms of service.